Sohini Das And Subhomoy Bhattacharjee

Stories by Sohini Das And Subhomoy Bhattacharjee

 Covaxin shows robust response

Covaxin shows robust response

Rediff.com   17 Dec 2020

Bharat Biotech is in the middle of conducting a phase 3 trial with 22,000 subjects.

COVID-19 vaccines likely to have longer shelf life

COVID-19 vaccines likely to have longer shelf life

Rediff.com   14 Dec 2020

A longer shelf life is critical, given many makers have started manufacturing vaccines and stockpiling them, so as to make them available in the market immediately after approval, reports Sohini Das.

Is this Indian Covid vaccine better than Pfizer's?

Is this Indian Covid vaccine better than Pfizer's?

Rediff.com   12 Dec 2020

India's first mRNA platform-based vaccine will remain stable at 2-8 degrees Celsius while Pfizer-BioNTech's vaccine needs minus 70 degrees Celsius and Moderna vaccine can remain stable for six months at minus 20 degrees Celsius, reports Sohini Das.

Covishield volunteer decides to move court against Serum Institute

Covishield volunteer decides to move court against Serum Institute

Rediff.com   11 Dec 2020

'Our client is suffering due to the ill-effects of the vaccine. He has to be compensated for his suffering. Further, a detailed investigation has to be done on the Covishield vaccine and its side-effects,' says the volunteer's advocate.

Why Modi visited Serum's Covid vaccine unit

Why Modi visited Serum's Covid vaccine unit

Rediff.com   10 Dec 2020

The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.

Serum Institute set to sign deal with Centre for Covishield

Serum Institute set to sign deal with Centre for Covishield

Rediff.com   9 Dec 2020

By January-February, it's expected to have at least 100 million doses for the Indian government, reports Sohini Das.

Revealed: Govt's COVID-19 vaccination plan

Revealed: Govt's COVID-19 vaccination plan

Rediff.com   8 Dec 2020

The modus operandi for immunising the country's 1.35 billion population in stages has been thrashed out in more than one meeting among top government officials in the health ministry and the Prime Minister's Office.

How Indian pharma bounced back from lockdown lows

How Indian pharma bounced back from lockdown lows

Rediff.com   7 Dec 2020

From rising prescriptions to the pharma sales force back on the field with full vigour and companies finally finding their feet with the digital marketing strategies - Indian drug makers have shown that medicine sales is certainly a sunshine sector.

Covid: How Pfizer plans to resolve cold storage issues in India

Covid: How Pfizer plans to resolve cold storage issues in India

Rediff.com   7 Dec 2020

The company has developed detailed logistical plans and tools to support effective vaccine transport, storage, and temperature monitoring. Sohini Das and Ruchika Chitravanshi report.

How states are preparing for Covid vaccine distribution

How states are preparing for Covid vaccine distribution

Rediff.com   2 Dec 2020

Each state has its own weak areas that need attention. Some states have already identified the gaps and sought the Centre's help. Vinay Umarji, Ishita Ayan Dutt, Samreen Ahmad and Sohini Das report.

India may get first Covid-19 vaccine by February

India may get first Covid-19 vaccine by February

Rediff.com   30 Nov 2020

The government plans to immunise 30 million people in the first phase, starting February, and by July, the target is to vaccinate 250 million people, reports Sohini Das.

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Indian Immunologicals to set up new vaccine plant, raise capacity by 35%

Rediff.com   26 Nov 2020

The company has a pipeline of viral vaccines including Zika, dengue, varicella, as well as a potential Covid-19 inoculation.

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Serum Institute to keep 200 mn doses of Covid vaccine ready by Jan

Rediff.com   13 Nov 2020

'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Pandemic pushes up demand for CT scanners; firms gear up to meet surge

Rediff.com   4 Nov 2020

Siemens Healthineers, one of the largest manufacturers of made-in-India CT scanners, has sold 80-100 such machines in the last 45 days. The medical technology firm typically sells 250 machines in a year.

Bharat Biotech starts Covaxin's at-risk manufacture

Bharat Biotech starts Covaxin's at-risk manufacture

Rediff.com   2 Nov 2020

The first vaccine candidate will be an intra-muscular one, followed by intra-dermal and nasal ones, depending on test results.

Why Dr Reddy's had to shut all its units

Why Dr Reddy's had to shut all its units

Rediff.com   25 Oct 2020

Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.

The chinks in India's arbitration laws

The chinks in India's arbitration laws

Rediff.com   22 Oct 2020

Treaty

Covid-19 impact: Low interest loans likely for vaccine companies

Covid-19 impact: Low interest loans likely for vaccine companies

Rediff.com   10 Oct 2020

While there has been no commitment from the government on the procurement of vaccines, initial volumes, or distribution plans, there is a likelihood that the low interest loans may be made available to these players only when the time to scale up manufacturing arises.

Covaxin: How Bharat Biotech plans to boost immunity

Covaxin: How Bharat Biotech plans to boost immunity

Rediff.com   6 Oct 2020

Adjuvants may be added to a vaccine to produce more antibodies and longer lasting immunity thus minimising the dose of antigen needed.

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Sales of Biocon's itolizumab surge as phase-4 clinical trials begin

Rediff.com   6 Oct 2020

In India, itolizumab, known by the brand name Alzumab, has been priced at Rs 8,000 per vial. Most patients require four vials for Covid-19 treatment, taking the cost of the therapy to Rs 32,000.